🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🇺🇸Real world analysis of 1L systemic therapy trends for metastatic ccRCC using Flatiron database (n=7,923) 🔹1L Rx pre-2018 (FDA approval for ipi/nivo): TKI (79%); post-2018: anti-PD-1 combo (58%) 🔹2L Rx pre-2018: TKI (39%), anti-PD-1 (31%); post-2018: TKI (45%), anti-PD-1 + TKI

Ab#5081 ASCO #ASCO24 👉 Higher BMI is prognostic for longer OS in pts with mHSPC. Analysis of pt level data from S1216 study. bit.ly/4aQuXOp #prostatecancer UroToday.com OncoAlert SWOG Cancer Research Network Neeraj Agarwal, MD, FASCO

Changes in treatment patterns and attrition rates in patients with metastatic clear cell #RenalCellCarcinoma. Presented by Gliceida Galarza, MD Huntsman Cancer Institute. #ASCO24 written coverage by Rashid K. Sayyid University of Toronto > bit.ly/4bXNSYA ASCO

Heartiest congratulations to Neeraj Agarwal, MD, FASCO and Adriana M Coletta, PhD, MS, RD for Huntsman Cancer Institute Collaborative Award for RO1 grant 👉 randomized trial of creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression

Just in JAMA Network Open 👉 Unacceptablely low rates of NGS testing in metastatic #ProstateCancer #bladdercancer in real world pts (worse in Black & Hispanic pts)Flatiron Health👇Proud of our postdoc, Chadi @chadihc98 , Yeonjung, George Georges Gebrael & team👇 terrific mentoring by

Wrapping up an amazing week at the AACR/ASCO Workshop on Methods in Clinical Cancer Research. Grateful for the opportunity to learn from pioneers in the field and spending the week meeting like-minded physicians ASCO AACR

Hosted Utah Hematology/Oncology Fellows fellows myeloid Jeopardy tonight and it was so fun! We have the best fellows!!! 💫💫💫Huntsman Cancer Institute UofUHeme

Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria #mmsm #myeloma | Manni Mohyuddin Huntsman Cancer Institute pubmed.ncbi.nlm.nih.gov/39314111/

Transplant in myeloma: individualized approaches needed depending on context, access and biology #mmsm #myeloma | Manni Mohyuddin Huntsman Cancer Institute nature.com/articles/s4140…

1/ 🚨 Now in Blood Cancer Journal - our multicenter description of IEC-associated enterocolitis as a novel toxicity of CAR-T in myeloma #MMsm. Typically non-bloody Gr3+ diarrhea starting ~3 mo after ide-cel or cilta-cel: 36% cases fatal in our series (n=14). nature.com/articles/s4140…

Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma #mmsm #myeloma | Gliceida Galarza, MD Huntsman Cancer Institute Blood Cancer Journal nature.com/articles/s4140…

Packed room SWOG Cancer Research Network GU committee 2024 fall meeting, with opening remarks by splernerMD 👉Congrats Umang Swami Huntsman Cancer Institute for receiving SWOG Cancer Research Network Dr. Vogelzang scholar award 👉consider supporting The Hope Foundation for Dr. Vogelzang fund👉 bit.ly/4dSbE8U Lucky Lara

CAR T-Cell Therapies Extend Treatment-Free Intervals in Multiple Myeloma With Careful Patient Selection and Toxicity Monitoring @MyelomaSLC Huntsman Cancer Institute #mmsm onclive.com/view/car-t-cel…

Just in CA: A Cancer Journal for Clinicians 👉Comprehensive review of efficacy & safety data of PARP inhibitors across cancer types #prostatecancer, #ovariancancer, #breastcancer & others 👉Open access weblink👉 bit.ly/42apBgy @chadihc98 GU Cancer Research Program @HuntsmanCancer  OncoAlert UroToday.com PCF Science

Congrats to 3 young investigators👇from GU Cancer Research Program @HuntsmanCancer for ASCO #GU25 Conquer Cancer, the ASCO Foundation Merit Award! Zeynep Irem Ozay, MD Nicolas Sayegh, MD #DiyaGarg Names of all investigators who received the award👉 bit.ly/40HI1ma Abstract search👉 bit.ly/3EfRs4O UroToday.com Prostate Cancer Foundation OncoAlert

Just in JAMA Network Open👉Flatiron Health Real world Rx data from >8500 pts w/ mRCC #kidneycancer 👉After 2018, only 38% & 14% of pts received 2nd & 3rd line Rx respectively👇bit.ly/41H22dp Thanks to my mentors Umang Swami Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO Cc OncoAlert UroToday.com

New #JITC article: Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT) bit.ly/4hHGQdh Gliceida Galarza, MD Benjamin L Maughan Huntsman Cancer Institute

#Myeloma Paper of the Day: Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in myeloma includes higher risk of prolonged transfusion dependence for both pRBC and G-CSF us, as well as higher thrombopoietin receptor agonist use: pubmed.ncbi.nlm.nih.gov/40203191/. #mmsm

#Myeloma Paper of the Day: Large retrospective analysis of 153 #PCL patients using new definition of ≥ 5% circulating plasma cells finds secondary PCL associated with a worse prognosis, with median OS of 3.2 months vs. 36.6 months for primary PCL: pubmed.ncbi.nlm.nih.gov/40241568/. #mmsm